logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
L

Lung Cancer-Targets and Therapy

IF3.3
论文数81
被引数427
期刊论文 81
发表时间
delete
Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study
deleteLung Cancer-Targets and Therapy
IF3.3
delete2026-10-13
delete0
deleteOAAI
deleteChih-Hsi Scott Kuo; Shigeki Umemura; Chin-Chou Wang; Shingo Matsumoto; How-Wen Ko; Fu-Tsai Chung; Ping-Chih Hsu; Hiroki Izumi; Yuji Shibata; Hibiki Udagawa; Kiyotaka Yoh; Yuri Murata; Koichi Goto; Cheng-Ta Yang
delete分享
delete收藏
Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?能否通过新型临床试验设计，将ALINA和ELEVATE研究中建立的2年辅助ALK TKI治疗期延长至超过2年，用于接受手术切除的早期ALK+非小细胞肺癌（一种易发生中枢神经系统转移的疾病）？
deleteLung Cancer-Targets and Therapy
IF3.3
delete2026-09-29
delete0
deleteOAAI
deleteVivian Thuy Tieu, Misako Nagasaka, Sai-Hong Ignatius Ou
delete分享
delete收藏
Healing of Post-Operative Tracheal Disruption in a Patient with Thymic Carcinoma on Adjuvant Immunotherapy胸腺癌患者术后气管断裂在辅助免疫治疗下的愈合
deleteLung Cancer-Targets and Therapy
IF3.3
delete2026-09-22
delete0
deleteOAAI
deleteJessica Lubisich; Hari B Keshava; Jeremy P Harris; Tjoson Tjoa; Cathleen J Park; Zhaohui L Arter; Sai-Hong Ignatius Ou; Misako Nagasaka
delete分享
delete收藏
Identification of JAML as an Immune-Associated Prognostic Marker in Non-Small Cell Lung Cancer鉴定JAML作为非小细胞肺癌的免疫相关预后标志物
deleteLung Cancer-Targets and Therapy
IF3.3
delete2026-09-02
delete0
deleteOAAI
deleteQin Tian; Fucheng Zhang; Chunyan Han
delete分享
delete收藏
Unilateral Scleral Icterus as a Rare Presentation of Choroidal Metastasis in Transdifferentiated EGFR-Mutant Lung Cancer: A Case Report and Review of the Literature单侧巩膜黄疸作为转分化EGFR突变型肺癌脉络膜转移的罕见表现：病例报告及文献综述
deleteLung Cancer-Targets and Therapy
IF3.3
delete2026-08-28
delete0
deleteOAAI
deleteOz Levinkron; Thubeena Manickavasagar; Sanjay Popat; Richard Scawn
delete分享
delete收藏
Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report在Pralsetinib进展后获得新型RETp.L730_G731insL突变的CCDC6-RET肺腺癌患者对Selpercatinib的治疗反应：一例病例报告
deleteLung Cancer-Targets and Therapy
IF3.3
delete2026-05-20
delete0
deleteOAAI
deleteChunyu Tian; Yang Zou; Jinxin Liu; Jing Zhao; Simiao Tian; Ying Liu; Gang Wang
delete分享
delete收藏
Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients免疫学血液生物标志物在预测不可靶向治疗晚期非小细胞肺癌患者化疗反应和生存结局中的效率
deleteLung Cancer-Targets and Therapy
IF3.3
delete2026-01-01
delete0
deleteOAAI
deleteLumjiaktase, Putthapoom; Kemawichanurat, Nanthisa; Santiwiwas, Kanthon; Kuttiyod, Thatchathum; Oranratnachai, Songporn; Trachu, Narumol; Monnamo, Nanamon; Khiewngam, Khantong; Simmalee, Kantapat; Reungwetwattana, Thanyanan
delete分享
delete收藏
Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study)阿来替尼在布加替尼后对晚期ALK+非小细胞肺癌的疗效（BrigALK2-GFPC 02-2019研究）
deletelung cancer targets and therapy
IF0
delete2025-08-12
delete0
deleteOAAI
deleteRenaud Descourt; Florian Guisier; Maurice Pérol; Jacques Cadranel; Helene Doubre; Michael Duruisseaux; Stéphane Culine; Bertrand Mennecier; Olivier Bylicki; Christos Chouaid; Laurent Greillier
delete分享
delete收藏
Epidermal Growth Factor Receptor Kinase Domain Duplication in Lung Adenocarcinoma with Sensitive Response to Afatinib: A Case Report and Literature Review表皮生长因子受体激酶域复制在敏感应答阿法替尼的肺腺癌中的病例报告及文献综述
deletelung cancer targets and therapy
IF0
delete2025-08-12
delete0
deleteOAAI
deleteShuangru Chen; Liting Zhang; Jun Wang; Jiayao Lu; Ye Chen; Mingzhu Ling
delete分享
delete收藏
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients吸烟者和从未吸烟者肺鳞癌患者的基因组与转录组特征
deletelung cancer targets and therapy
IF0
delete2025-06-28
delete0
deleteOAAI
deleteMatteo Canale; Alessandra Virga; Davide Angeli; Eugenio Fonzi; Letizia Gnetti; Alessandra Dubini; Gianluca Tedaldi; Milena Urbini; Giovanni Bocchialini; Elisabetta Petracci; Alberto Verlicchi; Paola Cravero; Fabrizio Citarella; Chiara Bennati; Kalliopi Andrikou; Angelo Delmonte; Lucio Crinò; Paolo Carbognani; Paola Ulivi; Luca Ampollini
delete分享
delete收藏
Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma评价免疫检查点抑制剂联合化疗作为一线疗法在肺肉瘤样癌中的有效性与安全性特征
deletelung cancer targets and therapy
IF0
delete2025-06-09
delete0
deleteOAAI
deleteHe Du, Xinyu Song, Fengying Wu
delete分享
delete收藏
Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer Cells阐明FASN在敏感和耐药EGFR突变非小细胞肺癌细胞中的肺癌干细胞中的作用
deletelung cancer targets and therapy
IF0
delete2025-05-27
delete0
deleteOAAI
deleteEmma Polonio-Alcalá; Sira Ausellé-Bosch; Gerard Riesco-Llach; Pablo Novales; Lidia Feliu; Marta Planas; Joaquim Ciurana; Teresa Puig
delete分享
delete收藏
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA; NCT03521154)LAURA研究完善了奥希替尼治疗EGFR阳性非小细胞肺癌（从IB期到IV期）的拼图：与安慰剂相比，辅助奥希替尼显著改善了不可切除III期EGFR突变非小细胞肺癌的无进展生存期和 CNS进展（LAURA; NCT03521154）
deletelung cancer targets and therapy
IF0
delete2025-04-25
delete0
deleteOAAI
deleteFaustine X Luo; Zhaohui Arter; Sai-Hong Ignatius Ou; Misako Nagasaka
delete分享
delete收藏
Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study越南早期可切除非小细胞肺癌患者中EGFR突变的患病率：EARLY-EGFR研究
deletelung cancer targets and therapy
IF0
delete2025-04-21
delete0
deleteOAAI
deleteTu Van Dao; Van Luong Dinh; Thanh Vinh Doan; Tri Le Phuong
delete分享
delete收藏
Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung CancerEGFR突变非小细胞肺癌转变为小细胞肺癌后，后续治疗对患者临床结局的影响
deletelung cancer targets and therapy
IF0
delete2025-04-12
delete0
deleteOAAI
deleteChing-Yi Chen; How-Wen Ko; Po-Wei Hu; Cheng-Yu Chang; Chung-Yu Chen; Shih-Chieh Chang; Yu-Chi Chiu; Yu-Feng Wei
delete分享
delete收藏
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I; II; III) of BRAF Mutated (BRAF+) NSCLCAACR GENIE数据库中BRAF突变（BRAF+）非小细胞肺癌（NSCLC）所有三类（I类、II类、III类）肿瘤突变负荷（TMB）的全面综述
deletelung cancer targets and therapy
IF0
delete2025-02-19
delete0
deleteOAAI
deleteZhaohui Liao Arter; Kevin Shieh; Misako Nagasaka; Sai-Hong Ignatius Ou
delete分享
delete收藏
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival
deleteLUNG CANCER-TARGETS AND THERAPY
IF3.3
delete2025-02-01
delete0
deleteOAAI
deleteCanale, Matteo; Urbini, Milena; Petracci, Elisabetta; Angeli, Davide; Tedaldi, Gianluca; Priano, Ilaria; Cravero, Paola; Flospergher, Michele; Andrikou, Kalliopi; Bennati, Chiara; Tassinari, Davide; Dubini, Alessandra; Rossi, Giulio; Panzacchi, Riccardo; Valli, Mirca; Bronte, Giuseppe; Crino, Lucio; Delmonte, Angelo; Ulivi, Paola
delete分享
delete收藏
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
deleteLUNG CANCER-TARGETS AND THERAPY
IF3.3
delete2024-12-01
delete0
deleteOAAI
deleteLee, Alexandria T. M.; Nagasaka, Misako
delete分享
delete收藏
Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung CarcinomaKRYSTAL-12中的Adagrasib打破了非小细胞肺癌中的KRASG12C谜语
deleteLUNG CANCER-TARGETS AND THERAPY
IF3.3
delete2024-10-01
delete0
deleteOAAI
deleteLuo, Faustine X.; Arter, Zhaohui Liao
delete分享
delete收藏
NRG1 Fusions in NSCLC: Being eNRGy ConsciousNSCLC中的NRG1融合: 有意识
deleteLUNG CANCER-TARGETS AND THERAPY
IF3.3
delete2024-10-01
delete1
deleteOAAI
deleteGupta, Brinda; Barrett, Laura Gosa; Liu, Stephen, V
delete分享
delete收藏